Kim M Linton

17PUBLICATIONS
152CO-AUTHORS
Molecular targetsHaematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 18, 2026
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

|Aug 20, 2026
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

|Jul 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL.

|Jan 06, 2026
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han

|Sep 08, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi, Anna Sureda, Sirpa Leppä

|Sep 08, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli

Pageof 3

Frequent Collaborators

5 joint publications

Pamela McKay

4 joint publications

Andrew J Davies

4 joint publications

Christopher P Fox

3 joint publications

Jessica Okosun